Acadia falls on Nuplazid safety concerns

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) fell $5.03 (23%) to $16.50 on Monday after CNN called out a November 2017 safety report from the non-profit group Institute for Safe Medication Practices (ISMP), which identified 244 deaths among 2,236 adverse event reports filed for patients taking Nuplazid pimavanserin to treat Parkinson's disease psychosis (PDP).

ISMP composes its reports using data from the FDA Adverse Event Reporting System (FAERS), a publicly available database created to collect adverse event data after a drug goes to market (see BioCentury Innovations, Oct. 5, 2017)...